HTBX Heat Biologics, Inc.

0  -1%
Previous Close 0.78
Open 0.78
Price To book 2.32
Market Cap 25.82M
Shares 33,526,000
Volume 279,307
Short Ratio 1.99
Av. Daily Volume 998,947

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing data released March 21, 2017.
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 2 trial did not meet primary endpoint - November 30, 2016.
Bladder cancer
Phase 1b data released December 6, 2016.
Non-small cell lung cancer (NSCLC)

Latest News

  1. Heat Biologics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.
  2. OncoSec collaboration data 'promising' for embattled Heat Bio
  3. Heat Biologics Presents New Preclinical Data from OncoSec Collaboration at the American Association for Cancer Research (AACR) Annual Meeting
  4. Heat Biologics Reports Fiscal Year 2016 Financial Results
  5. Heat Biologics Closes Public Offering of 5,000,000 Shares of Common Stock
  6. 2 Health Care Stocks Crushed on Thursday
  7. Heat Biologics Prices Offering of 5,000,000 Shares of Common Stock
  8. Heat Biologics Announces Proposed Public Offering of Common Stock
  9. Heat Biologics Lung Cancer Drug Posts Good Results
  10. Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor
  11. Heat Biologics, Inc. to Present at The MicroCap Conference on April 4th in New York City
  12. Heat Biologics faces threat of delisting – again
  13. Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine
  14. Heat Biologics Lung Cancer Drug Combo Succeeds
  15. Heat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2
  16. Austin cancer-fighting startup to rejoin public company it spun out from in 2012
  17. Blog Coverage Heat Biologics Acquires Controlling Stake in Immuno-Oncology Company Pelican Therapeutics
  18. Heat Biologics to Present at 29th Annual ROTH Conference
  19. Durham outfit to acquire Texas company in a cash-stock deal
  20. Heat Biologics Announces Agreement to Acquire Pelican Therapeutics

SEC Filings

  1. PRE 14A - Other preliminary proxy statements 17796714
  2. 424B5 - Prospectus (Rule 424(b)(5)) 17795413
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 17764421
  4. 8-K - Current report 17750554
  5. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17727951
  6. 8-K - Current report 17727947
  7. 8-K - Current report 17710955
  8. 424B2 - Prospectus (Rule 424(b)(2)) 17710950
  9. 8-K - Current report 17708170
  10. 424B5 - Prospectus (Rule 424(b)(5)) 17708163